Publications

2025

• Outcomes of older adults and frail patients receiving idecabtagene vicleucel: a CIBMTR studyAkhtar O, Oloyede T, Brazauskas R, Afrough A, Hashmi H, Sidana S, Ahmed N, Bye M, Hansen D, Ferreri C, Dhakal B, Dhanda D, Harrison M, Kitali A, Landau H, Mirza A, Patel J, Patwardhan P, Qazilbash M, Patel K, Nishihori T, Ganguly S, Gowda L, Anderson L, Pasquini M, Usmani S, Freeman C. Outcomes of older adults and frail patients receiving idecabtagene vicleucel: a CIBMTR study. Blood Advances 2025, 9: 1587-1592. PMID: 39786391, DOI: 10.1182/bloodadvances.2024014970.

  
• Imetelstat in myeloid malignancies: current data and future directionsBidikian A, Bewersdorf J, Kewan T, Podoltsev N, Stahl M, Zeidan A. Imetelstat in myeloid malignancies: current data and future directions. Expert Review Of Anticancer Therapy 2025, ahead-of-print: 1-12. PMID: 40116730, DOI: 10.1080/14737140.2025.2482721.

  
• Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statementBorate U, Pugh K, Waller A, Welkie R, Huang Y, Bewersdorf J, Stahl M, DeZern A, Platzbecker U, Sekeres M, Wei A, Buckstein R, Roboz G, Savona M, Loghavi S, Hasserjian R, Fenaux P, Sallman D, Hourigan C, Della Porta M, Nimer S, Little R, Santini V, Efficace F, Taylor J, Garcia-Manero G, Odenike O, Kim T, Halene S, Komrokji R, Griffiths E, Greenberg P, Xu M, Xie Z, Bejar R, Sanz G, Patnaik M, Figueroa M, Carraway H, Abdel-Wahab O, Starczynowski D, Padron E, Boultwood J, Gore S, Daver N, Churpek J, Majeti R, Bennett J, List A, Brunner A, Zeidan A. Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement. Blood 2025, 145: 1369-1381. PMID: 40146152, DOI: 10.1182/blood.2023023717.

  1

  

  1 Total citation

  1 Recent citation

  n/a Field Citation Ratio

  n/a Relative Citation Ratio

  
• Contemporary understanding of myeloid-derived suppressor cells in the acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) tumor microenvironmentAlhajahjeh A, Stahl M, Kim T, Kewan T, Stempel J, Zeidan A, Bewersdorf J. Contemporary understanding of myeloid-derived suppressor cells in the acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) tumor microenvironment. Expert Review Of Anticancer Therapy 2025, ahead-of-print: 1-22. PMID: 40122075, DOI: 10.1080/14737140.2025.2483855.

  
• American Society of Hematology living guidelines on use of anticoagulation for thromboprophylaxis for patients with COVID-19: executive summarySiegal D, Tseng E, Schünemann H, Angchaisuksiri P, Cuker A, Dane K, DeSancho M, Diuguid D, Griffin D, Klok F, Lee A, Neumann I, Pai A, Righini M, Sanfilippo K, Terrell D, Akl E, Al Jabiri R, Al Jabiri Y, Barbara A, Bognanni A, Akl I, Boulos M, Brignardello-Petersen R, Chan M, Charide R, Colunga-Lozano L, Dearness K, Darzi A, Hussein H, Karam S, Kolb P, Mansour R, Morgano G, Morsi R, Muti-Schünemann G, Nadim M, Noori A, Philip B, Piggott T, Qiu Y, Benitez Y, Schünemann F, Stevens A, Solo K, Wiercioch W, Mustafa R, Nieuwlaat R. American Society of Hematology living guidelines on use of anticoagulation for thromboprophylaxis for patients with COVID-19: executive summary. Blood Advances 2025, 9: 1247-1260. PMID: 39437797, DOI: 10.1182/bloodadvances.2024014219.

  1

  

  1 Total citation

  1 Recent citation

  n/a Field Citation Ratio

  n/a Relative Citation Ratio

  
• In the time of COVID-19: challenges, successes and lessons learned from studies in cancer patientsMack P, Crawford J, Chang A, Yin A, Klein S, Shea P, Hirsch F, Zidar D, Simon V, Gleason C, McBride R, Cordon-Cardo C, VanOudenhove J, Halene S, Lee F, Mantis N, Kushi L, Weiskopf D, Merchant A, Reckamp K, Skarbinski J, Figueiredo J. In the time of COVID-19: challenges, successes and lessons learned from studies in cancer patients. Journal Of The National Cancer Institute 2025, djaf073. PMID: 40127178, DOI: 10.1093/jnci/djaf073.

  
• Quality of English‐ and Spanish‐language online content about prostate cancer genetics: Insights into potential contributors to prostate cancer disparitiesAbusamra S, Cholán V, Giri V, Vadaparampil S, Pérez‐Rosas V, Rivera A, Nolasco T, Camacho M, Byrne N, Loeb S. Quality of English‐ and Spanish‐language online content about prostate cancer genetics: Insights into potential contributors to prostate cancer disparities. BJUI Compass 2025, 6: e70011. PMID: 40129444, PMCID: PMC11930542, DOI: 10.1002/bco2.70011.

  
• The Role of the Interventional Radiologist in Stopping Bleeding in Cancer PatientsFish A, Madoff D. The Role of the Interventional Radiologist in Stopping Bleeding in Cancer Patients. Current Oncology Reports 2025, 1-7. PMID: 40120057, DOI: 10.1007/s11912-025-01663-5.

  
• Genomic Landscape of Late-Stage Gastric Cancer: Analysis From KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 StudiesJanjigian Y, Cecchini M, Shitara K, Enzinger P, Wainberg Z, Chau I, Satoh T, Lee J, Nebozhyn M, Loboda A, Kobie J, Vajdi A, Shih C, Cristescu R, Cao Z. Genomic Landscape of Late-Stage Gastric Cancer: Analysis From KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Studies. JCO Precision Oncology 2025, 9: e2400456. PMID: 40117530, PMCID: PMC11949223, DOI: 10.1200/po-24-00456.

  
• Scientific Advancements in Gene Therapies: Opportunities for Global Regulatory ConvergenceOlaghere J, Williams D, Farrar J, Büning H, Calhoun C, Ho T, Inamdar M, Liu D, Makani J, Nyarko K, Ruiz S, Tisdale J, McCune J, Boadi E, for the FDA R. Scientific Advancements in Gene Therapies: Opportunities for Global Regulatory Convergence. Biomedicines 2025, 13: 758. PMID: 40149734, PMCID: PMC11940732, DOI: 10.3390/biomedicines13030758.

  
• Psychedelics for Cancer Pain and Associated Psychological Distress: A Narrative Review of a Potential StrategyBelitzky E, Carvalho L, Taylor M, Ortiz C, Baum L, Fiellin D, Lustberg M. Psychedelics for Cancer Pain and Associated Psychological Distress: A Narrative Review of a Potential Strategy. Cancer Medicine 2025, 14: e70586. PMID: 40052631, DOI: 10.1002/cam4.70586.

  
• Mediators of Racial Inequities in Non‐Small Cell Lung Cancer CareHamid S, Lee D, Herrin J, Yu J, Pollack C, Dean L, Gaddy J, Oladele C, Feder S, Canavan M, Nunez-Smith M, Soulos P, Gross C. Mediators of Racial Inequities in Non‐Small Cell Lung Cancer Care. Cancer Medicine 2025, 14: e70757. PMID: 40052387, DOI: 10.1002/cam4.70757.
• Machine learning-based spatial characterization of tumor-immune microenvironment in the EORTC 10994/BIG 1-00 early breast cancer trialZerdes I, Matikas A, Mezheyeuski A, Manikis G, Acs B, Johansson H, Boyaci C, Boman C, Poncet C, Ignatiadis M, Bai Y, Rimm D, Cameron D, Bonnefoi H, Bergh J, MacGrogan G, Foukakis T. Machine learning-based spatial characterization of tumor-immune microenvironment in the EORTC 10994/BIG 1-00 early breast cancer trial. Npj Breast Cancer 2025, 11: 23. PMID: 40055382, DOI: 10.1038/s41523-025-00730-1.

  
• Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases.Weiss S, Djureinovic D, Wei W, Tran T, Austin M, Markowitz J, Eroglu Z, Khushalani N, Hegde U, Cohen J, Sznol M, Anderson G, Johnson B, Piteo C, Mahajan A, Adeniran A, Jilaveanu L, Goldberg S, Chiang V, Forsyth P, Kluger H. Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases. Journal Of Clinical Oncology 2025, jco2402219. PMID: 40048689, DOI: 10.1200/jco-24-02219.

  1

  

  1 Total citation

  1 Recent citation

  n/a Field Citation Ratio

  n/a Relative Citation Ratio

  
• Quantitative Protein Expression of Antibody-Drug Conjugate Targets in EGFR Mutated and Wild-Type Non-Small Cell Lung Cancer.Trontzas I, He M, Wurtz A, Robbins C, Robinson N, Bates K, Liu M, Aung T, Scott L, Chan N, Burela S, Schillo J, Liebler D, Hill S, Morrison R, Vathiotis I, Syrigos K, Goldberg S, Politi K, Rimm D. Quantitative Protein Expression of Antibody-Drug Conjugate Targets in EGFR Mutated and Wild-Type Non-Small Cell Lung Cancer. Clinical Cancer Research 2025 PMID: 40047548, DOI: 10.1158/1078-0432.ccr-24-3347.

  
• The Association Between Sex and Lung Cancer Screening Adherence to Follow-Up in a Cohort of VeteransBernstein E, Bade B, DeRycke E, Lerz K, Zeghlache R, Rose M, Kravetz J, Farmer M, Bastian L, Akgün K, Cain H. The Association Between Sex and Lung Cancer Screening Adherence to Follow-Up in a Cohort of Veterans. Journal Of Women's Health 2025 PMID: 40045919, DOI: 10.1089/jwh.2024.0780.

  
• A plain language summary of the ASCERTAIN trial: oral decitabine and cedazuridine versus intravenous decitabine for MDS or CMMLGarcia-Manero G, McCloskey J, Griffiths E, Yee K, Zeidan A, Al-Kali A, Deeg H, Sabloff M, Keating M, Zhu N, Gabrail N, Fazal S, Maly J, Odenike O, DeZern A, O'Connell C, Roboz G, Busque L, Buckstein R, Amin H, Leber B, Shastri A, Oganesian A, Keer H, Azab M, Savona M. A plain language summary of the ASCERTAIN trial: oral decitabine and cedazuridine versus intravenous decitabine for MDS or CMML. Future Oncology 2025, 21: 929-941. PMID: 40051275, PMCID: PMC11938952, DOI: 10.1080/14796694.2025.2468578.

  
• Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial.Petrylak D, Ratta R, Matsubara N, Korbenfeld E, Gafanov R, Mourey L, Todenhöfer T, Gurney H, Kramer G, Bergman A, Zalewski P, De Santis M, Armstrong A, Gerritsen W, Pachynski R, Byun S, Retz M, Levesque E, McDermott R, Bracarda S, Manneh R, Levartovsky M, Li X, Schloss C, Poehlein C, Fizazi K. Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial. Journal Of Clinical Oncology 2025, jco2401283. PMID: 40043230, DOI: 10.1200/jco-24-01283.

  1

  

  1 Total citation

  1 Recent citation

  n/a Field Citation Ratio

  n/a Relative Citation Ratio

  
• Integrating epidemiology and genomics data to estimate the prevalence of acquired cysteine drug targets in the U.S. cancer patient populationArun A, Liarakos D, Mendiratta G, Kim J, Goshua G, Olson P, Stites E. Integrating epidemiology and genomics data to estimate the prevalence of acquired cysteine drug targets in the U.S. cancer patient population. The Pharmacogenomics Journal 2025, 25: 5. PMID: 40044654, DOI: 10.1038/s41397-025-00364-3.
• Top advances of the year: Small cell lung cancerShields M, Chiang A, Byers L. Top advances of the year: Small cell lung cancer. Cancer 2025, 131: e35770. PMID: 40040254, DOI: 10.1002/cncr.35770.

  
• Determinants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapiesCallari M, Dugo M, Barreca M, Győrffy B, Galbardi B, Vigano L, Locatelli A, Dall’Ara C, Ferrarini M, Bisagni G, Colleoni M, Mansutti M, Zamagni C, Del Mastro L, Zambelli S, Frassoldati A, Biasi O, Pusztai L, Valagussa P, Viale G, Gianni L, Bianchini G. Determinants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapies. Nature Communications 2025, 16: 2195. PMID: 40038334, PMCID: PMC11880565, DOI: 10.1038/s41467-025-57293-9.

  
• Portal and Hepatic Vein Embolization vs Portal Venous Embolization Alone in Cirrhotic and Non-cirrhotic Swine: A Pilot StudyTefera J, Kuhn T, Matuschewski N, Meister E, Nguyenová J, Kao T, Mutonga M, Bitar R, Kahl V, Zhang X, Shewarega A, Chapiro J, Madoff D. Portal and Hepatic Vein Embolization vs Portal Venous Embolization Alone in Cirrhotic and Non-cirrhotic Swine: A Pilot Study. Journal Of Vascular And Interventional Radiology 2025 PMID: 40043833, DOI: 10.1016/j.jvir.2025.02.028.
• Beyond the Marrow–Moving Toward a Systemic Perspective of Radiation-Induced CytopeniasBrowning S, Lourdes M, Neparidze N, Robinson T. Beyond the Marrow–Moving Toward a Systemic Perspective of Radiation-Induced Cytopenias. International Journal Of Radiation Oncology • Biology • Physics 2025, 121: 1039-1041. PMID: 39988417, DOI: 10.1016/j.ijrobp.2024.11.100.
• OATP1B-type Transport Function Is a Determinant of Aromatase Inhibitor-Associated Arthralgia Susceptibility.Taheri H, Li Y, Huang K, Ahmed E, Jin Y, Drabison T, Yang Y, Kulp S, Young N, Li J, Cheng X, Corps K, Coss C, Vaughn J, Lustberg M, Sparreboom A, Hu S. OATP1B-type Transport Function Is a Determinant of Aromatase Inhibitor-Associated Arthralgia Susceptibility. Cancer Research Communications 2025, 5: 496-510. PMID: 40062557, PMCID: PMC11948302, DOI: 10.1158/2767-9764.crc-24-0475.

  
• A composite 18F-FDG PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant pertuzumab and trastuzumab in HER2-positive breast cancer (TBCRC026)Hennessy M, Cimino-Mathews A, Carter J, Kachergus J, Ma Y, Leal J, Solnes L, Abramson V, Carey L, Rimawi M, Specht J, Storniolo A, Vaklavas C, Krop I, Winer E, Denbow R, Valero V, Wolff A, Wahl R, Huang C, Stearns V, Thompson E, Connolly R. A composite 18F-FDG PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant pertuzumab and trastuzumab in HER2-positive breast cancer (TBCRC026). The Breast 2025, 81: 104432. PMID: 40049115, PMCID: PMC11928837, DOI: 10.1016/j.breast.2025.104432.

  
• Real-world outcomes with T-VEC in patients with anti-PD-1 resistant in-transit disease from melanoma and Merkel cell carcinomaSu D, McNamara M, Kaszycki M, Frey A, Ishizuka J, Costa P, Tran T, Kluger H, Clune J, Weiss S, Olino K. Real-world outcomes with T-VEC in patients with anti-PD-1 resistant in-transit disease from melanoma and Merkel cell carcinoma. Surgical Oncology Insight 2025, 2: 100120. DOI: 10.1016/j.soi.2024.100120.
• 47P Final analysis of the randomized phase II cohort of CM24 with nivolumab and chemotherapy in pancreatic cancer and potential serum biomarkersSchickler M, Mercade T, Cecchini M, Garcia-Carbonero R, Golan T, Perets R, Borazanci E, Trujillo M, Ponz M, Al-Hallak M, Pant S, Boni V, Saavedra O, De Miguel M, Leal A, Martin A, Nadal T, David H, Reuveni H. 47P Final analysis of the randomized phase II cohort of CM24 with nivolumab and chemotherapy in pancreatic cancer and potential serum biomarkers. ESMO Open 2025, 10: 104206. DOI: 10.1016/j.esmoop.2025.104206.

  
• Response and Outcomes of Patients with IDH1/2 Mutated Accelerated/Blast-Phase Myeloproliferative NeoplasmsGoldberg L, Yoon J, Johnston H, Davidson M, Siddon A, Shallis R, Chen E, Burkart M, Oh T, Iyer S, Madarang E, Muthiah C, Kassner J, Rampal R, Murthy S, Bradley T, Abaza Y, Garcia J, Gupta V, Pettit K, Odenike O, Cursio J, Patel A. Response and Outcomes of Patients with IDH1/2 Mutated Accelerated/Blast-Phase Myeloproliferative Neoplasms. Blood Neoplasia 2025, 100089. DOI: 10.1016/j.bneo.2025.100089.

  
• 226 Identification of Nectin-2 as a Potential Novel Antibody Drug Conjugate Target in Breast CancerShan N, Wang Y, Zhu X, Pusztai L, Zhan H. 226 Identification of Nectin-2 as a Potential Novel Antibody Drug Conjugate Target in Breast Cancer. Laboratory Investigation 2025, 105: 102450. DOI: 10.1016/j.labinv.2024.102450.
• 127 Analytical Validation and Prospective Study of a High-Sensitivity HER2 (HS-HER2) Quantitative Immunofluorescence Assay for Enhanced Stratification of HER2-Low Breast Cancer PatientsChan N, Gaule P, Benanto J, Robbins C, Scott L, Hill S, Morrison R, Liebler D, Fulton R, Rimm D. 127 Analytical Validation and Prospective Study of a High-Sensitivity HER2 (HS-HER2) Quantitative Immunofluorescence Assay for Enhanced Stratification of HER2-Low Breast Cancer Patients. Laboratory Investigation 2025, 105: 102351. DOI: 10.1016/j.labinv.2024.102351.
• 119 Reading vs Measuring: Comparison of Pathologist-Based Scores to Analytic MeasurementsBates K, Fernandez A, Martinez-Morilla S, Chan N, Benanto J, Reisenbichler E, Rimm D. 119 Reading vs Measuring: Comparison of Pathologist-Based Scores to Analytic Measurements. Laboratory Investigation 2025, 105: 102343. DOI: 10.1016/j.labinv.2024.102343.
• DEVELOPMENT OF EX VIVO PATIENT-DERIVED MODELS TO UNCOVER THE TUMOR-IMMUNE MICROENVIRONMENT IN RENAL CELL CARCINOMAKashima S, Gupta R, Moritz V, Sadak K, Walker J, Adeniran A, Humphrey P, Dinulescu D, Palmer D, Hammond S, Bosenberg M, Hurwitz M, Kenney P, Braun D. DEVELOPMENT OF EX VIVO PATIENT-DERIVED MODELS TO UNCOVER THE TUMOR-IMMUNE MICROENVIRONMENT IN RENAL CELL CARCINOMA. Urologic Oncology Seminars And Original Investigations 2025, 43: 22-23. DOI: 10.1016/j.urolonc.2024.12.057.
• 831 AXL Receptor Tyrosine Kinase Expression in Metastatic Renal Cell Carcinoma: Insights from the METEOR trialLaimon Y, Paul M, Jammihal T, Ghandour F, Ahmar N, Simsek B, Matar S, Denize T, Mohanna R, De Oliveira G, Delcea A, Shukla S, Braun D, Sun M, Aftab D, Saad E, Machaalani M, Xie W, Choueiri T, Signoretti S. 831 AXL Receptor Tyrosine Kinase Expression in Metastatic Renal Cell Carcinoma: Insights from the METEOR trial. Laboratory Investigation 2025, 105: 103064. DOI: 10.1016/j.labinv.2024.103064.
• 796 Tertiary Lymphoid Structures Predict Response to First-Line Nivolumab Therapy in Advanced Renal Cell Carcinoma: Findings from the HCRN GU16-260 Clinical TrialAhmar N, Simsek B, Jegede O, Matar S, Savla V, Laimon Y, Mohanna R, De Oliveira G, Sheshdeh A, Delcea A, Paul M, Choueiri T, Xie W, Freeman G, Braun D, Haas N, Hammers H, Bilen M, Stein M, Sosman J, Wu C, McDermott D, Atkins M, Signoretti S. 796 Tertiary Lymphoid Structures Predict Response to First-Line Nivolumab Therapy in Advanced Renal Cell Carcinoma: Findings from the HCRN GU16-260 Clinical Trial. Laboratory Investigation 2025, 105: 103029. DOI: 10.1016/j.labinv.2024.103029.
• Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid TumorsGambardella V, Ong M, Rodriguez-Ruiz M, Machiels J, Sanmamed M, Galvao V, Spreafico A, Renouf D, Luen S, Galot R, de Spéville B, Calvo E, Naing A, Curdt S, Kolben T, Rossmann E, Tanos T, Smart K, Amann M, Xie Y, Xu L, Alcaide E, Städler N, Justies N, Boetsch C, Karanikas V, Schnetzler G, Rohrberg K. Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors. Cancer Research Communications 2025, 5: 422-432. PMID: 39983024, PMCID: PMC11891644, DOI: 10.1158/2767-9764.crc-24-0638.

  
• Advancing drug development in myelodysplastic syndromesMina A, McGraw K, Cunningham L, Kim N, Jen E, Calvo K, Ehrlich L, Aplan P, Garcia-Manero G, Foran J, Garcia J, Zeidan A, DeZern A, Komrokji R, Sekeres M, Scott B, Buckstein R, Tinsley-Vance S, Verma A, Wroblewski T, Pavletic S, Norsworthy K. Advancing drug development in myelodysplastic syndromes. Blood Advances 2025, 9: 1095-1104. PMID: 39786387, PMCID: PMC11914162, DOI: 10.1182/bloodadvances.2024014865.

  
• Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitorsSkoulidis F, Araujo H, Do M, Qian Y, Sun X, Cobo A, Le J, Montesion M, Palmer R, Jahchan N, Juan J, Min C, Yu Y, Pan X, Arbour K, Vokes N, Schmidt S, Molkentine D, Owen D, Memmott R, Patil P, Marmarelis M, Awad M, Murray J, Hellyer J, Gainor J, Dimou A, Bestvina C, Shu C, Riess J, Blakely C, Pecot C, Mezquita L, Tabbó F, Scheffler M, Digumarthy S, Mooradian M, Sacher A, Lau S, Saltos A, Rotow J, Johnson R, Liu C, Stewart T, Goldberg S, Killam J, Walther Z, Schalper K, Davies K, Woodcock M, Anagnostou V, Marrone K, Forde P, Ricciuti B, Venkatraman D, Van Allen E, Cummings A, Goldman J, Shaish H, Kier M, Katz S, Aggarwal C, Ni Y, Azok J, Segal J, Ritterhouse L, Neal J, Lacroix L, Elamin Y, Negrao M, Le X, Lam V, Lewis W, Kemp H, Carter B, Roth J, Swisher S, Lee R, Zhou T, Poteete A, Kong Y, Takehara T, Paula A, Parra Cuentas E, Behrens C, Wistuba I, Zhang J, Blumenschein G, Gay C, Byers L, Gibbons D, Tsao A, Lee J, Bivona T, Camidge D, Gray J, Leighl N, Levy B, Brahmer J, Garassino M, Gandara D, Garon E, Rizvi N, Scagliotti G, Wolf J, Planchard D, Besse B, Herbst R, Wakelee H, Pennell N, Shaw A, Jänne P, Carbone D, Hellmann M, Rudin C, Albacker L, Mann H, Zhu Z, Lai Z, Stewart R, Peters S, Johnson M, Wong K, Huang A, Winslow M, Rosen M, Winters I, Papadimitrakopoulou V, Cascone T, Jewsbury P, Heymach J. Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature 2025, 639: e19-e19. PMID: 40016449, PMCID: PMC11903295, DOI: 10.1038/s41586-025-08767-9.

  
• Comparison of prognostic accuracy of HCC staging systems in patients undergoing TACEKasolowsky V, Gross M, Madoff D, Duncan J, Taddei T, Strazzabosco M, Jaffe A, Chapiro J. Comparison of prognostic accuracy of HCC staging systems in patients undergoing TACE. Clinical Imaging 2025, 120: 110438. PMID: 40049074, DOI: 10.1016/j.clinimag.2025.110438.

  
• HIF regulates multiple translated endogenous retroviruses: Implications for cancer immunotherapyJiang Q, Braun D, Clauser K, Ramesh V, Shirole N, Duke-Cohan J, Nabilsi N, Kramer N, Forman C, Lippincott I, Klaeger S, Phulphagar K, Chea V, Kim N, Vanasse A, Saad E, Parsons T, Carr-Reynolds M, Carulli I, Pinjusic K, Jiang Y, Li R, Syamala S, Rachimi S, Verzani E, Stevens J, Lane W, Camp S, Meli K, Pappalardi M, Herbert Z, Qiu X, Cejas P, Long H, Shukla S, Van Allen E, Choueiri T, Churchman L, Abelin J, Gurer C, MacBeath G, Childs R, Carr S, Keskin D, Wu C, Kaelin W. HIF regulates multiple translated endogenous retroviruses: Implications for cancer immunotherapy. Cell 2025 PMID: 40023154, DOI: 10.1016/j.cell.2025.01.046.

  1

  

  1 Total citation

  1 Recent citation

  n/a Field Citation Ratio

  n/a Relative Citation Ratio

  
• Presence of tertiary lymphoid structures and exhausted tissue-resident T cells determines clinical response to PD-1 blockade in renal cell carcinoma.Hugaboom M, Wirth L, Street K, Ruthen N, Jegede O, Schindler N, Shah V, Zaemes J, El Ahmar N, Matar S, Savla V, Choueiri T, Denize T, West D, McDermott D, Plimack E, Sosman J, Haas N, Stein M, Alter R, Bilen M, Hurwitz M, Hammers H, Signoretti S, Atkins M, Wu C, Braun D. Presence of tertiary lymphoid structures and exhausted tissue-resident T cells determines clinical response to PD-1 blockade in renal cell carcinoma. Cancer Discovery 2025, of1-of21. PMID: 39992403, DOI: 10.1158/2159-8290.cd-24-0991.

  1

  

  1 Total citation

  1 Recent citation

  n/a Field Citation Ratio

  n/a Relative Citation Ratio

  
• PD-1H (VISTA) expression in cutaneous squamous cell carcinoma is correlated with T cell infiltration and activationKidacki M, Cho C, Lopez-Giraldez F, Huang B, He J, Gaule P, Chen L, Vesely M. PD-1H (VISTA) expression in cutaneous squamous cell carcinoma is correlated with T cell infiltration and activation. Journal Of Investigative Dermatology 2025 PMID: 39983979, DOI: 10.1016/j.jid.2025.01.030.

  
• Assessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapyShaw R, Yoon J, Johnston H, Davidson M, Siddon A, Shallis R, Chen E, Burkart M, Oh T, Iyer S, Madarang E, Muthiah C, Kassner J, Rampal R, Guru Murthy G, Bradley T, Abaza Y, Garcia J, Gupta V, Pettit K, Odenike O, Patel A. Assessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapy. Blood Advances 2025 PMID: 39969200, DOI: 10.1182/bloodadvances.2024015712.

  
• Clinical-genomic profiling of MDS to inform allo-HSCT: Recommendations from an international panel on behalf of the EBMTGurnari C, Robin M, Adès L, Aljurf M, Almeida A, Duarte F, Bernard E, Cutler C, Della Porta M, de Witte T, DeZern A, Drozd-Sokolowska J, Duncavage E, Fenaux P, Gagelmann N, Garcia-Manero G, Haferlach C, Haferlach T, Hasserjian R, Hellstrom-Lindberg E, Jacoby M, Kulasekararaj A, Lindsley R, Maciejewski J, Makishima H, Malcovati L, Mittelman M, Myhre A, Ogawa S, Onida F, Papaemmanuil E, Passweg J, Platzbecker U, Pleyer L, Raj K, Santini V, Sureda A, Tobiasson M, Voso M, Yakoub-Agha I, Zeidan A, Walter M, Kröger N, McLornan D, Cazzola M. Clinical-genomic profiling of MDS to inform allo-HSCT: Recommendations from an international panel on behalf of the EBMT. Blood 2025 PMID: 39970324, DOI: 10.1182/blood.2024025131.

  
• US Geriatric Assessment Practices for Older Adults Undergoing Hematopoietic Cell Transplantation or CAR T- cell therapy: An ASTCT Physician Survey from the Aging Special Interest Group and Committee on Practice GuidelinesMunshi P, Olin R, Wall S, McCurdy S, Al-Juhaishi T, Baker J, Bhatt V, Chokr N, Dahi P, DeFilipp Z, Espinoza-Gutarra M, Farhan S, Gowda L, Hamilton B, Inamoto Y, Jayani R, Kharfan-Dabaja M, Lin R, Meyers G, Mishra A, Murthy H, Nawas M, Rosko A, Ruiz M, Sorror M, Sung A, Carpenter P, Hamadani M, Artz A. US Geriatric Assessment Practices for Older Adults Undergoing Hematopoietic Cell Transplantation or CAR T- cell therapy: An ASTCT Physician Survey from the Aging Special Interest Group and Committee on Practice Guidelines. Transplantation And Cellular Therapy 2025 PMID: 39961473, DOI: 10.1016/j.jtct.2025.02.014.

  
• KLF2 maintains lineage fidelity and suppresses CD8 T cell exhaustion during acute LCMV infectionFagerberg E, Attanasio J, Dien C, Singh J, Kessler E, Abdullah L, Shen J, Hunt B, Connolly K, De Brouwer E, He J, Iyer N, Buck J, Borr E, Damo M, Foster G, Giles J, Huang Y, Tsang J, Krishnaswamy S, Cui W, Joshi N. KLF2 maintains lineage fidelity and suppresses CD8 T cell exhaustion during acute LCMV infection. Science 2025, 387: eadn2337. PMID: 39946463, DOI: 10.1126/science.adn2337.

  3

  

  3 Total citations

  3 Recent citations

  n/a Field Citation Ratio

  n/a Relative Citation Ratio

  
• Efficacy of cannabinoids for the prophylaxis of chemotherapy-induced nausea and vomiting—a systematic review and meta-analysisChow R, Basu A, Kaur J, Hui D, Im J, Prsic E, Boldt G, Lock M, Eng L, Ng T, Zimmermann C, Scotte F. Efficacy of cannabinoids for the prophylaxis of chemotherapy-induced nausea and vomiting—a systematic review and meta-analysis. Supportive Care In Cancer 2025, 33: 193. PMID: 39953210, PMCID: PMC11828838, DOI: 10.1007/s00520-025-09251-w.

  
• A pooled analysis evaluating prognostic significance of Residual Cancer Burden in invasive lobular breast cancerMukhtar R, Gottipati S, Yau C, López-Tarruella S, Earl H, Hayward L, Hiller L, Osdoit M, van der Noordaa M, de Croze D, Hamy A, Laé M, Reyal F, Sonke G, Steenbruggen T, van Seijen M, Wesseling J, Martín M, del Monte-Millán M, Boughey J, Goetz M, Hoskin T, Valero V, Edge S, Abraham J, Bartlett J, Caldas C, Dunn J, Provenzano E, Sammut S, Thomas J, Graham A, Hall P, Mackintosh L, Fan F, Godwin A, Schwensen K, Sharma P, DeMichele A, Cole K, Pusztai L, Kim M, J van ’t Veer L, Cameron D, Esserman L, Fraser Symmans W. A pooled analysis evaluating prognostic significance of Residual Cancer Burden in invasive lobular breast cancer. Npj Breast Cancer 2025, 11: 14. PMID: 39948079, PMCID: PMC11825822, DOI: 10.1038/s41523-025-00720-3.

  
• Oncologic Outcomes with De-Escalation of Axillary Surgery After Neoadjuvant Chemotherapy for Breast Cancer: Results from > 1500 Patients on the I-SPY2 Clinical TrialBoughey J, Yu H, Switalla K, Velle L, Lopes A, Wallace A, Lancaster R, Reyna C, Tuttle T, Jaskowiak N, Tchou J, Rao R, Lee M, Naik A, Golshan M, Arciero C, Sauder C, Matsen C, Yau C, Esserman L, Mukhtar R. Oncologic Outcomes with De-Escalation of Axillary Surgery After Neoadjuvant Chemotherapy for Breast Cancer: Results from > 1500 Patients on the I-SPY2 Clinical Trial. Annals Of Surgical Oncology 2025, 1-14. PMID: 39946078, DOI: 10.1245/s10434-025-16973-y.

  
• Inpatient Immunotherapy Outcomes Study: A Multicenter Retrospective Analysis.Riaz F, Vaughn J, Zhu H, Dickerson J, Sayegh H, Brongiel S, Baldwin E, Kier M, Zaemes J, Hearn C, Abdelghany O, Cohen R, Parikh R, Reuss J, Prsic E, Doroshow D. Inpatient Immunotherapy Outcomes Study: A Multicenter Retrospective Analysis. JCO Oncology Practice 2025, op2400788. PMID: 39937997, DOI: 10.1200/op-24-00788.

  1

  

  1 Total citation

  1 Recent citation

  n/a Field Citation Ratio

  n/a Relative Citation Ratio

  
• Racial and ethnic disparities in conversion to mastectomy following lumpectomyKhubchandani J, KC M, Dey P, Proussaloglou E, Valero M, Berger E, Park T, Gross C, Butler P, Fayanju O, Winer E, Golshan M, Greenup R. Racial and ethnic disparities in conversion to mastectomy following lumpectomy. Breast Cancer Research And Treatment 2025, 211: 99-110. PMID: 39937397, DOI: 10.1007/s10549-025-07625-6.

  
• Statistical considerations for evaluating treatment effect under various non-proportional hazard scenarios.Zhang X, Greene E, Blaha O, Wei W. Statistical considerations for evaluating treatment effect under various non-proportional hazard scenarios. Statistical Methods In Medical Research 2025, 9622802241313297. PMID: 39930911, DOI: 10.1177/09622802241313297.

  
• Bayesian model averaging for randomized dose optimization trials in multiple indications.Wei W, Lin J. Bayesian model averaging for randomized dose optimization trials in multiple indications. J Biopharm Stat 2025, 1-13. PMID: 39930766, DOI: 10.1080/10543406.2025.2450325.

  
• Promoting Reasonable Career Expectations and Maximizing Professional Fulfillment for Academic Oncologists: ASCO Recommendations for Academic Medical Centers.Winer E, Levit L, Basch E, Chavez-MacGregor M, Dubois R, Eckhardt S, Ellis L, Hudis C, Schrag D, Speers C, Wilky B, Tibbits M, Spence R, Garrett-Mayer E. Promoting Reasonable Career Expectations and Maximizing Professional Fulfillment for Academic Oncologists: ASCO Recommendations for Academic Medical Centers. Journal Of Clinical Oncology 2025, jco2402246. PMID: 39928904, DOI: 10.1200/jco-24-02246.

  
• Local definitive therapy (LDT) utilization patterns and outcomes in chromophobe renal cell carcinoma (chRCC) with metachronous metastasis: A multi-institution study.Dizman N, Doshi S, Knezevic A, Feinaj A, Sayegh N, Hobeika C, Alaghehbandan R, Rives H, Zengin Z, Braun D, Zibelman M, McGregor B, Hammers H, Ged Y, Ornstein M, Msaouel P, Hahn A, Voss M. Local definitive therapy (LDT) utilization patterns and outcomes in chromophobe renal cell carcinoma (chRCC) with metachronous metastasis: A multi-institution study. Journal Of Clinical Oncology 2025, 43: 503-503. DOI: 10.1200/jco.2025.43.5_suppl.503.
• Survival of patients with metastatic renal cell carcinoma with or without brain metastases.Hurwitz M, Considine B, Hasson N, Savion Gaiger N, Nelson M, Chiang V, Kluger H, Braun D, Schoenfeld D, Sznol M, Leapman M. Survival of patients with metastatic renal cell carcinoma with or without brain metastases. Journal Of Clinical Oncology 2025, 43: 476-476. DOI: 10.1200/jco.2025.43.5_suppl.476.

  1

  

  1 Total citation

  1 Recent citation

  n/a Field Citation Ratio

  n/a Relative Citation Ratio
• A comprehensive evaluation of gene expression-based signatures for detecting tertiary lymphoid structures (TLS) in metastatic renal cell carcinoma (mRCC).Saad E, El Ahmar N, Simsek B, Jegede O, Matar S, Mohanna R, Yekeduz E, McDermott D, Plimack E, Sosman J, Haas N, Hurwitz M, Hammers H, Van Allen E, Choueiri T, Atkins M, Signoretti S, Braun D. A comprehensive evaluation of gene expression-based signatures for detecting tertiary lymphoid structures (TLS) in metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2025, 43: 591-591. DOI: 10.1200/jco.2025.43.5_suppl.591.
• INTerpath-004: A phase 2, randomized, double-blind study of adjuvant pembrolizumab (pembro) with V940 (mRNA-4157) or placebo for renal cell carcinoma (RCC).Motzer R, Braun D, Powles T, Gurney H, Fong L, George D, Haas N, McDermott D, Shuch B, Meehan R, Posadas T, Wu S, Elfiky A, Choueiri T. INTerpath-004: A phase 2, randomized, double-blind study of adjuvant pembrolizumab (pembro) with V940 (mRNA-4157) or placebo for renal cell carcinoma (RCC). Journal Of Clinical Oncology 2025, 43: tps610-tps610. DOI: 10.1200/jco.2025.43.5_suppl.tps610.
• Avelumab first-line maintenance (1LM) in patients (pts) with advanced urothelial carcinoma (aUC) with or without diabetes mellitus (DM): Long-term outcomes from JAVELIN Bladder 100.Gupta S, Grivas P, Park S, Petrylak D, Tyroller K, Hoffman J, Bellmunt J. Avelumab first-line maintenance (1LM) in patients (pts) with advanced urothelial carcinoma (aUC) with or without diabetes mellitus (DM): Long-term outcomes from JAVELIN Bladder 100. Journal Of Clinical Oncology 2025, 43: 869-869. DOI: 10.1200/jco.2025.43.5_suppl.869.

  
• A phase III randomized trial of eribulin (E) with gemcitabine vs standard of care (SOC) for patients (pts) with metastatic urothelial carcinoma (mUC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937—Updated design.Sadeghi S, Callis S, Lara P, Berg S, Brown J, Bangs R, Nakagawa D, Daneshmand S, Ian Murchie Jr., Flaig T, Petrylak D, Lerner S. A phase III randomized trial of eribulin (E) with gemcitabine vs standard of care (SOC) for patients (pts) with metastatic urothelial carcinoma (mUC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937—Updated design. Journal Of Clinical Oncology 2025, 43: tps887-tps887. DOI: 10.1200/jco.2025.43.5_suppl.tps887.
• Cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC): Final results of COSMIC-313.Albiges L, Motzer R, Trevino S, Kanesvaran R, Centkowski P, Reimers M, Sade J, Pouessel D, Biscaldi E, Esteban E, Arranz Arija J, Tykodi S, Ma H, Zhou L, Van Kooten Losio M, Simmons A, Rangwala F, Braun D, Choueiri T, Powles T. Cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC): Final results of COSMIC-313. Journal Of Clinical Oncology 2025, 43: 438-438. DOI: 10.1200/jco.2025.43.5_suppl.438.

  1

  

  1 Total citation

  1 Recent citation

  n/a Field Citation Ratio

  n/a Relative Citation Ratio

  
• Comprehensive proteomic profiling of plasma samples associated with response or resistance to immune checkpoint inhibitors (ICI) in patients with renal cell carcinoma (RCC).Kashima S, Xu W, Canniff J, Saliby R, Sun M, Lee G, Machaalani M, Signoretti S, McGregor B, McKay R, Choueiri T, Braun D. Comprehensive proteomic profiling of plasma samples associated with response or resistance to immune checkpoint inhibitors (ICI) in patients with renal cell carcinoma (RCC). Journal Of Clinical Oncology 2025, 43: 562-562. DOI: 10.1200/jco.2025.43.5_suppl.562.
• Metabolic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma.Saliby R, Labaki C, Jammihal T, Soulati H, Gallegos J, Peris A, McCurry D, Shah V, Poduval D, El Zarif T, El Ahmar N, Nabil Laimon Y, Bagheri Sheshdeh A, Eid M, Krajewski K, Signoretti S, Van Allen E, Shukla S, Choueiri T, Braun D. Metabolic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma. Journal Of Clinical Oncology 2025, 43: 571-571. DOI: 10.1200/jco.2025.43.5_suppl.571.
• Investigation of ferroptosis and mTOR signaling in chromophobe renal cell carcinoma (ChRCC).Madsen K, Labaki C, Saad E, Alchoueiry M, Bi K, Hobeika C, Bakouny Z, Priolo C, Khabibullin D, Schindler N, Camp S, Saliby R, Heng D, Van Allen E, Shukla S, Henske E, Choueiri T, Braun D. Investigation of ferroptosis and mTOR signaling in chromophobe renal cell carcinoma (ChRCC). Journal Of Clinical Oncology 2025, 43: 583-583. DOI: 10.1200/jco.2025.43.5_suppl.583.
• Association between PD-1 expression on tumor-infiltrating regulatory T cells and resistance to first-line nivolumab in advanced clear cell renal cell carcinoma: Insights from the HCRN GU16-260 clinical trial.Mohanna R, Simsek B, El Ahmar N, Jegede O, Matar S, Paul M, Nabil Laimon Y, Roberti De Oliveira G, Delcea A, Choueiri T, Braun D, Haas N, Hammers H, Bilen M, Stein M, Sosman J, Wu C, McDermott D, Atkins M, Signoretti S. Association between PD-1 expression on tumor-infiltrating regulatory T cells and resistance to first-line nivolumab in advanced clear cell renal cell carcinoma: Insights from the HCRN GU16-260 clinical trial. Journal Of Clinical Oncology 2025, 43: 590-590. DOI: 10.1200/jco.2025.43.5_suppl.590.
• Randomized Phase II Study to Assess the Role of Single-Agent Nivolumab to Maintain Remission in Acute Myeloid LeukemiaPyzer A, Dillon L, Sharon E, Karrison T, Zha Y, Fulton N, Gui G, Andrew G, Streicher H, Sweet K, Yaghmour G, Liu J, Jonas B, Schimmer A, Grant S, Zeidan A, Hildebrandt G, Lowrey C, Mattison R, Palmisiano N, Salhotra A, Tzachanis D, Baer M, Lin T, Patel P, Chen H, Stadler W, Odenike O, Larson R, Gajewski T, Hourigan C, Stock W, Liu H. Randomized Phase II Study to Assess the Role of Single-Agent Nivolumab to Maintain Remission in Acute Myeloid Leukemia. Blood Advances 2025 PMID: 39928953, DOI: 10.1182/bloodadvances.2024015176.

  
• Nanrilkefusp alfa (SOT101), an IL-15 receptor βγ superagonist, as a single agent or with anti-PD-1 in patients with advanced cancersChampiat S, Garralda E, Galvao V, Cassier P, Gomez-Roca C, Korakis I, Grell P, Naing A, LoRusso P, Mikyskova R, Podzimkova N, Reinis M, Ouali K, Schoenenberger A, Kiemle-Kallee J, Tillmanns S, Sachse R, Moebius U, Spisek R, Bechard D, Jelinkova L, Adkins I, Marabelle A. Nanrilkefusp alfa (SOT101), an IL-15 receptor βγ superagonist, as a single agent or with anti-PD-1 in patients with advanced cancers. Cell Reports Medicine 2025, 6: 101967. PMID: 39933529, PMCID: PMC11866505, DOI: 10.1016/j.xcrm.2025.101967.

  
• Olaparib in treatment‐refractory isocitrate dehydrogenase 1 (IDH1)– and IDH2‐mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trialCecchini M, Pilat M, Uboha N, Azad N, Cho M, Davis E, Ahnert J, Tinoco G, Shapiro G, Khagi S, Powers B, Spencer K, Groisberg R, Drappatz J, Chen L, Das B, Bao X, Li J, Narayan A, Vu D, Patel A, Niger M, Doroshow D, Durecki D, Boerner S, Bindra R, Ivy P, Shyr D, Shyr Y, LoRusso P. Olaparib in treatment‐refractory isocitrate dehydrogenase 1 (IDH1)– and IDH2‐mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trial. Cancer 2025, 131: e35755. PMID: 39917990, DOI: 10.1002/cncr.35755.

  
• Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody Drug Conjugate TAK-500.Appleman V, Matsuda A, Ganno M, Zhang D, Rosentrater E, Maldonado Lopez A, Porciuncula A, Hatten T, Christensen C, Merrigan S, Lee H, Lee M, Wang C, Dong L, Huang J, Iartchouk N, Wang J, Xu H, Yoneyama T, Piatkov K, Haridas S, Harbison C, Gregory R, Parent A, Lineberry N, Arendt C, Schalper K, Abu-Yousif A. Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody Drug Conjugate TAK-500. Cancer Immunology Research 2025 PMID: 39918395, DOI: 10.1158/2326-6066.cir-24-0103.
• Selinexor plus ruxolitinib in JAK inhibitor treatment-naïve myelofibrosis: SENTRY Phase 3 study designMascarenhas J, Maher K, Rampal R, Bose P, Podoltsev N, Hong J, Chai Y, Kye S, Method M, Harrison C, . Selinexor plus ruxolitinib in JAK inhibitor treatment-naïve myelofibrosis: SENTRY Phase 3 study design. Future Oncology 2025, 21: 807-813. PMID: 39911057, PMCID: PMC11916360, DOI: 10.1080/14796694.2025.2461393.

  
• A neoantigen vaccine generates antitumour immunity in renal cell carcinomaBraun D, Moranzoni G, Chea V, McGregor B, Blass E, Tu C, Vanasse A, Forman C, Forman J, Afeyan A, Schindler N, Liu Y, Li S, Southard J, Chang S, Hirsch M, LeBoeuf N, Olive O, Mehndiratta A, Greenslade H, Shetty K, Klaeger S, Sarkizova S, Pedersen C, Mossanen M, Carulli I, Tarren A, Duke-Cohan J, Howard A, Iorgulescu J, Shim B, Simon J, Signoretti S, Aster J, Elagina L, Carr S, Leshchiner I, Getz G, Gabriel S, Hacohen N, Olsen L, Oliveira G, Neuberg D, Livak K, Shukla S, Fritsch E, Wu C, Keskin D, Ott P, Choueiri T. A neoantigen vaccine generates antitumour immunity in renal cell carcinoma. Nature 2025, 639: 474-482. PMID: 39910301, PMCID: PMC11903305, DOI: 10.1038/s41586-024-08507-5.

  4

  

  4 Total citations

  4 Recent citations

  n/a Field Citation Ratio

  n/a Relative Citation Ratio

  
• Real-world enrollment for a prospective clinico-genomic database using a pragmatic technology-enabled platformExarchos A, Bourla A, Kaur M, Schulze K, Maund S, Cao Y, Zhao Y, Williams E, Gaffey S, Zuniga R, Lakhanpal S, Antic V, Doral M, Sy J, Meropol N, Chiang A. Real-world enrollment for a prospective clinico-genomic database using a pragmatic technology-enabled platform. Contemporary Clinical Trials Communications 2025, 44: 101446. PMID: 40027276, PMCID: PMC11869879, DOI: 10.1016/j.conctc.2025.101446.
• Patient-reported strategies for prevention and treatment of chemotherapy-induced peripheral neuropathyHertz D, Tanay M, Tofthagen C, Rossi E, Bernasconi D, Sheffield K, Carlson M, Nekhlyudov L, Grech L, Von Ah D, Mayo S, Ruddy K, Chan A, Alberti P, Lustberg M. Patient-reported strategies for prevention and treatment of chemotherapy-induced peripheral neuropathy. Supportive Care In Cancer 2025, 33: 142. PMID: 39899120, DOI: 10.1007/s00520-025-09190-6.

  1

  

  1 Total citation

  1 Recent citation

  n/a Field Citation Ratio

  n/a Relative Citation Ratio

  
• A Slow RevealBrowning S, Dhaliwal G, Dill A, Khandakar B, Sofair A. A Slow Reveal. Journal Of General Internal Medicine 2025, 1-6. PMID: 39900872, DOI: 10.1007/s11606-025-09373-1.
• Insights into treatment of patients with mycosis fungoides or Sézary syndrome using mogamulizumabFoss F, Kim Y, Scarisbrick J, Akilov O, Ristuccia R, Dwyer K, Wu W, Bagot M. Insights into treatment of patients with mycosis fungoides or Sézary syndrome using mogamulizumab. Journal Of Dermatological Treatment 2025, 36: 2438794. PMID: 39894454, DOI: 10.1080/09546634.2024.2438794.

  
• Surgical Management of Breast Cancer Liver MetastasisRahnemai-Azar A, Selby L, Lustberg M, Pawlik T. Surgical Management of Breast Cancer Liver Metastasis. Hematology/Oncology Clinics Of North America 2025, 39: 25-35. PMID: 39510675, DOI: 10.1016/j.hoc.2024.08.012.
• Outcomes after Allogeneic Transplantation with Reduced Intensity Conditioning and Post Transplant Cyclophosphamide GvHD Prophylaxis in T-Cell Lymphomas: A Single Institution ExperienceTaborda C, Isufi I, Bar N, Sethi T, Gowda L, Perreault S, Roberts K, Seropian S, Foss F. Outcomes after Allogeneic Transplantation with Reduced Intensity Conditioning and Post Transplant Cyclophosphamide GvHD Prophylaxis in T-Cell Lymphomas: A Single Institution Experience. Transplantation And Cellular Therapy 2025, 31: s393-s394. DOI: 10.1016/j.jtct.2025.01.606.
• [177Lu]Lu-DOTA-TATE chez les patients nouvellement diagnostiqués atteints de TNE GEP avancées bien différenciées de grade (G)2 et 3 : analyse primaire de NETTER-2Singh S, Halperin D, Myrehaug S, Hermann K, Pavel M, Kunz P, Chasen B, Capdevila J, Tafuto S, Oh D, Yoo C, Falk S, Halfdanarson T, Folitar I, Zhang Y, Santoro P, Aimone P, de Herder W, Ferone D. [177Lu]Lu-DOTA-TATE chez les patients nouvellement diagnostiqués atteints de TNE GEP avancées bien différenciées de grade (G)2 et 3 : analyse primaire de NETTER-2. Nuklearmedizin - NuclearMedicine 2025, 49: 21-22. DOI: 10.1016/j.mednuc.2024.12.046.
• Long-Term Benefits in Patient-Reported Outcomes and Time to Next Anti-Myeloma Therapy of Ciltacabtagene Autoleucel (Cilta-cel) Versus Standard of Care for Patients with Lenalidomide-Refractory Multiple Myeloma: Results from the Phase 3 Cartitude-4 Clinical TrialBar N, Mina R, Mylin A, Yokoyama H, Magen H, Alsdorf W, Minnema M, Shune L, Isufi I, Harrison S, Shah U, De Champlain A, Gries K, Chen D, Li Q, Yeh T, Slaughter A, Lonardi C, Benachour N, Ghosh A, Deraedt W, Vogel M, Lendvai N, Patel N, Filho O, Florendo E, Karlin L, Weisel K. Long-Term Benefits in Patient-Reported Outcomes and Time to Next Anti-Myeloma Therapy of Ciltacabtagene Autoleucel (Cilta-cel) Versus Standard of Care for Patients with Lenalidomide-Refractory Multiple Myeloma: Results from the Phase 3 Cartitude-4 Clinical Trial. Transplantation And Cellular Therapy 2025, 31: s404-s405. DOI: 10.1016/j.jtct.2025.01.623.
• Ciltacabtagene Autoleucel (Cilta-cel) Vs Standard of Care (SoC) in Patients with Lenalidomide (Len)-Refractory Multiple Myeloma (MM) after 1–3 Lines of Therapy: Minimal Residual Disease (MRD) Negativity in the Phase 3 Cartitude-4 TrialPopat R, Oriol A, Cavo M, Karlin L, Avivi I, Roeloffzen W, Kim S, Lipe B, Bar N, Horvath N, Spencer A, Min C, Chen D, Li Q, Li K, Slaughter A, Lonardi C, Benachour N, Ghosh A, Vogel M, Lendvai N, Lengil T, Patel N, Filho O, Florendo E, Lin Y. Ciltacabtagene Autoleucel (Cilta-cel) Vs Standard of Care (SoC) in Patients with Lenalidomide (Len)-Refractory Multiple Myeloma (MM) after 1–3 Lines of Therapy: Minimal Residual Disease (MRD) Negativity in the Phase 3 Cartitude-4 Trial. Transplantation And Cellular Therapy 2025, 31: s35. DOI: 10.1016/j.jtct.2025.01.047.
• TSC-100 and TSC-101 Demonstrate the Potential to Reduce Relapse Rates and Increase Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT) with Reduced Intensity Conditioning (RIC): Preliminary Results from the Phase 1 Alloha Trial (NCT05473910)Al Malki M, Keyzner A, Popat U, Chen Y, Suh H, Jain T, Solh M, Snow A, Pineiro L, Gill S, Gowda L, Uberti J, White T, Wang Y, Nguyen C, Louis C, Chattopadhyay S, Matzko M, Reshef R. TSC-100 and TSC-101 Demonstrate the Potential to Reduce Relapse Rates and Increase Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT) with Reduced Intensity Conditioning (RIC): Preliminary Results from the Phase 1 Alloha Trial (NCT05473910). Transplantation And Cellular Therapy 2025, 31: s59-s60. DOI: 10.1016/j.jtct.2025.01.096.
• Pralatrexate injection combined with oral leucovorin for mucositis management in PTCL/CTCL treatment: a multicenter phase 2 trialIyer S, Dakhil S, Shinohara M, Zain J, Acosta M, Foss F. Pralatrexate injection combined with oral leucovorin for mucositis management in PTCL/CTCL treatment: a multicenter phase 2 trial. Blood Neoplasia 2025, 2: 100055. DOI: 10.1016/j.bneo.2024.100055.
• Effectiveness and Safety Outcomes of Standard of Care (SOC) Lisocabtagene Maraleucel (liso-cel) in Patients (Pts) with Relapsed or Refractory (R/R) Transformed Large B-Cell Lymphoma (tLBCL): Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) RegistryIsufi I, Crombie J, Frigault M, Andreadis C, Lin Y, Mirza A, Kim S, Bernasconi D, Toron F, Krimmel T, Roy D, Pasquini M, Ahmed S. Effectiveness and Safety Outcomes of Standard of Care (SOC) Lisocabtagene Maraleucel (liso-cel) in Patients (Pts) with Relapsed or Refractory (R/R) Transformed Large B-Cell Lymphoma (tLBCL): Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry. Transplantation And Cellular Therapy 2025, 31: s215. DOI: 10.1016/j.jtct.2025.01.329.

  1

  

  1 Total citation

  1 Recent citation

  n/a Field Citation Ratio

  n/a Relative Citation Ratio
• A Phase I/IB Trial of Pembrolizumab and Trametinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Enriched for KRAS MutationsRiess J, Lara M, Luxardi G, de Rodas M, Shimoda M, Kelly K, Lara P, Beckett L, Monjazeb A, Schalper K, Maverakis E, Gandara D. A Phase I/IB Trial of Pembrolizumab and Trametinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Enriched for KRAS Mutations. JTO Clinical And Research Reports 2025, 100806. DOI: 10.1016/j.jtocrr.2025.100806.
• Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic MelanomaMunoz-Couselo E, Rivas A, Sandhu S, Long G, Sanmamed M, Spreafico A, Buchbinder E, Sznol M, Prenen H, Fedenko A, Milhem M, Fernandez A, Grob J, Demidov L, Robert C, Habigt C, Evers S, Sleiman N, Dejardin D, Ardeshir C, Martin N, Boetsch C, Charo J, Teichgräber V, Kraxner A, Keshelava N, Bechter O. Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma. Cancer Research Communications 2025, 5: 358-368. PMID: 39895413, PMCID: PMC11848832, DOI: 10.1158/2767-9764.crc-24-0601.

  1

  

  1 Total citation

  1 Recent citation

  n/a Field Citation Ratio

  n/a Relative Citation Ratio

  
• Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortiumHan J, Koh M, Boussi L, Sorial M, McCabe S, Peng L, Singh S, Eche-Ugwu I, Gabler J, Turizo M, MacVicar C, Garg A, Disciullo A, Chopra K, Lenart A, Nwodo E, Barnes J, Koh M, Miranda E, Chiattone C, Stuver R, Horwitz S, Merrill M, Jacobsen E, Manni M, Civallero M, Skrypets T, Lymboussaki A, Federico M, Kim Y, Kim J, Cho J, Eipe T, Shet T, Sridhar E, Shetty A, Saha S, Jain H, Sengar M, Van Der Weyden C, Prince H, Hamouche R, Murdashvili T, Foss F, Gentilini M, Casadei B, Zinzani P, Okatani T, Yoshida N, Yoon S, Kim W, Panchoo G, Mohamed Z, Verburgh E, Alturas J, Al-Mansour M, Ford J, Cabrera M, Ku A, Bhagat G, Ma H, Sawas A, Kariya K, Iwasaki M, Bhanushali F, O’Connor O, Marchi E, Shen C, Shah D, Jain S. Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortium. Blood Advances 2025, 9: 583-602. PMID: 39481087, PMCID: PMC11821408, DOI: 10.1182/bloodadvances.2024014674.

  1

  

  1 Total citation

  1 Recent citation

  n/a Field Citation Ratio

  n/a Relative Citation Ratio

  
• Correction: PIK3CAH1047R- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signalingCheng H, Liu P, Ohlson C, Xu E, Symonds L, Isabella A, Muller W, Lin N, Krop I, Roberts T, Winer E, Arteaga C, Zhao J. Correction: PIK3CAH1047R- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling. Oncogene 2025, 44: 478-479. PMID: 39890968, DOI: 10.1038/s41388-025-03281-8.
• Enteral and parenteral nutrition in patients with cancer: complication rates compared—updated systematic review and meta-analysisChow R, Im J, Arends J, Del Fabbro E, Mortensen-Truscott L, Qeska D, Balaji S, Walsh C, Watson G, Lock M, Prsic E, Eng L, Zimmermann C, Bruera E. Enteral and parenteral nutrition in patients with cancer: complication rates compared—updated systematic review and meta-analysis. BMJ Supportive & Palliative Care 2025, spcare-2024-005244. PMID: 39890439, DOI: 10.1136/spcare-2024-005244.

  
• Adjuvant Atezolizumab for Early Triple-Negative Breast CancerIgnatiadis M, Bailey A, McArthur H, El-abed S, de Azambuja E, Metzger O, Chui S, Dieterich M, Perretti T, Shearer-Kang E, Molinero L, Steger G, Jassem J, Lee S, Higgins M, Zarba J, Schmidt M, Gomez H, Zotano A, Moscetti L, Chiu J, Munzone E, Ben-Baruch N, Bajetta E, Ohno S, Im S, Werutsky G, Gal-Yam E, Farre X, Tseng L, Jacot W, Gluz O, Shao Z, Shparyk Y, Zimina A, Winer E, Cameron D, Viale G, Saji S, Gelber R, Piccart M. Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer. JAMA 2025, 333: 1150-1160. PMID: 39883436, PMCID: PMC11783246, DOI: 10.1001/jama.2024.26886.

  3

  

  3 Total citations

  3 Recent citations

  n/a Field Citation Ratio

  n/a Relative Citation Ratio

  
• Reconstructing Covert ConsciousnessFischer D, Edlow B, Freeman H, Alaiev D, Wu Q, Ware J, Detre J, Aguirre G. Reconstructing Covert Consciousness. Neurology 2025, 104: e210208. PMID: 39883908, PMCID: PMC11781786, DOI: 10.1212/wnl.0000000000210208.

  1

  

  1 Total citation

  1 Recent citation

  n/a Field Citation Ratio

  n/a Relative Citation Ratio
• State of Professional Well-Being, Satisfaction, and Career Plans Among US Oncologists in 2023Schenkel C, Levit L, Kirkwood K, Spence R, Burke J, Gallagher C, Garrett-Mayer E, McGinnis M, Morgante J, Page R, Paice J, Tetzlaff E, Winer E, Hlubocky F, Shanafelt T. State of Professional Well-Being, Satisfaction, and Career Plans Among US Oncologists in 2023. 2025, 2: e2400010. PMID: 39906334, PMCID: PMC11789616, DOI: 10.1200/oa.24.00010.

  
• Evaluation of navigation and robotic systems for percutaneous image-guided interventions: A novel metric for advanced imaging and artificial intelligence integrationCornelis F, Filippiadis D, Wiggermann P, Solomon S, Madoff D, Milot L, Bodard S. Evaluation of navigation and robotic systems for percutaneous image-guided interventions: A novel metric for advanced imaging and artificial intelligence integration. Diagnostic And Interventional Imaging 2025 PMID: 39884887, DOI: 10.1016/j.diii.2025.01.004.

  2

  

  2 Total citations

  2 Recent citations

  n/a Field Citation Ratio

  n/a Relative Citation Ratio
• FieldsAlpert A. Fields. JAMA 2025, 333: 352-352. DOI: 10.1001/jama.2024.18180.

  1

  

  1 Total citation

  1 Recent citation

  n/a Field Citation Ratio

  n/a Relative Citation Ratio

  
• Personalized frailty risk assessment in long-term survivors of colorectal cancer.Forman R, Westvold S, Long J, Fan J, Hyslop T, Yasin F, Conlin K, Jacobson S, Silber A, Wang S, Leapman M, Leeds I, Cecchini M, Spees L, Wheeler S, Gross C, Oeffinger K, Dinan M. Personalized frailty risk assessment in long-term survivors of colorectal cancer. Journal Of Clinical Oncology 2025, 43: 65-65. DOI: 10.1200/jco.2025.43.4_suppl.65.
• Outcomes in management of locally advanced rectal cancer with total neoadjuvant therapy in an underserved population.Ganguly A, Paladiya R, Ingawale S, Giri S, Abbagoni V, Thumar J. Outcomes in management of locally advanced rectal cancer with total neoadjuvant therapy in an underserved population. Journal Of Clinical Oncology 2025, 43: 208-208. DOI: 10.1200/jco.2025.43.4_suppl.208.
• Utility of computed tomography (CT) –based staging of mismatch repair deficient (dMMR) colon cancer.Linhares S, Srikumar T, Shin C, Mathur M, Mongiu A, Leeds I, Pantel H, Cecchini M. Utility of computed tomography (CT) –based staging of mismatch repair deficient (dMMR) colon cancer. Journal Of Clinical Oncology 2025, 43: 45-45. DOI: 10.1200/jco.2025.43.4_suppl.45.
• Phase 1b portion of the ACTION-1 phase 1b/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177Lu somatostatin analogue (SSA) therapy: Safety and efficacy findings.Strosberg J, Morris M, Ulaner G, Halperin D, Mehr S, Li D, Soares H, Anthony L, Kotiah S, Jacene H, Tesselaar M, Kunz P, Ferreira D, Li J, Ma K, Rearden J, Moran S, Hope T, Singh S. Phase 1b portion of the ACTION-1 phase 1b/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177Lu somatostatin analogue (SSA) therapy: Safety and efficacy findings. Journal Of Clinical Oncology 2025, 43: 661-661. DOI: 10.1200/jco.2025.43.4_suppl.661.
• Predictors of late recurrence of colorectal cancer (CRC) among older long-term survivors using claims-based evidence.Yasin F, Westvold S, Long J, Fan J, Hyslop T, Leeds I, Cecchini M, Gross C, Dinan M. Predictors of late recurrence of colorectal cancer (CRC) among older long-term survivors using claims-based evidence. Journal Of Clinical Oncology 2025, 43: 66-66. DOI: 10.1200/jco.2025.43.4_suppl.66.
• Editorial: Two decades of targeted therapies in hematology: new targets and novel combinationsCardoso B, Neparidze N. Editorial: Two decades of targeted therapies in hematology: new targets and novel combinations. Frontiers In Hematology 2025, 4: 1548984. DOI: 10.3389/frhem.2025.1548984.

  
• Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced splicing factor-mutant myeloid malignanciesBewersdorf J, Mi X, Lu B, Kuykendall A, Sallman D, Patel M, Stevens D, Philipovskiy A, Sutamtewagul G, Masarova L, Keiffer G, Verma A, Bhagwat N, Wang M, Moore A, Rager J, Heiser D, Ro S, Hong W, Abdel-Wahab O, Stein E. Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced splicing factor-mutant myeloid malignancies. Leukemia 2025, 39: 765-769. PMID: 39856223, PMCID: PMC11879867, DOI: 10.1038/s41375-025-02515-8.

  
• A Call for a Neoadjuvant Kidney Cancer Consortium: Lessons Learned from Other Cancer TypesBex A, Jewett M, Lewis B, Abel E, Albiges L, Berg S, Bratslavsky G, Braun D, Brugarolas J, Choueiri T, Finelli A, George D, Haas N, Hakimi A, Hammers H, Hirsch M, Jonasch E, Kapur P, Linehan W, Master V, McGregor B, McKay R, Mehra R, Pal S, Poteat S, Powles T, Rossi S, Shapiro D, Signoretti S, Singer E, Stravin C, Tannir N, Vaishampayan U, Xu W, Stewart G. A Call for a Neoadjuvant Kidney Cancer Consortium: Lessons Learned from Other Cancer Types. European Urology 2025, 87: 385-389. PMID: 39855942, DOI: 10.1016/j.eururo.2025.01.007.